BCAR3 and plasma cell myeloma: Conversely, in multiple myeloma (MM), high BCAR3 expression correlates with a favorable prognosis, including improved event-free and overall survival rates, while its low expression at diagnosis could predict early relapse, affirming BCAR3’s status as an independent prognostic factor and potential biomarker [11].